TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21473790
Drug: Vorinostat at
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat at the maximum-tolerated dose
Study: 21474353
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose glyceryl triacetate (GTA) at 4.5 g/kg/d for 4.5 and 6 months respectively
Study: 21474353
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose glyceryl triacetate (GTA) at up to 0.25 g/kg/d
Study: 21475692
Drug: High-caloric (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-caloric (600 kcal) high-protein (20 g) oral nutritional supplement
Study: 21478218
Drug: Rituximab (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1,000 mg) administered as two intravenous infusions 15 days apart
Study: 21478385
Drug: High on-aspirin
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High on-aspirin platelet reactivity (HAPR)
Study: 21478385
Drug: Dual high
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual high on-treatment platelet reactivity (DAPR)
Study: 21478385
Drug: No high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: No high on-treatment platelet reactivity
Study: 21478385
Drug: No high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: No high on-treatment platelet reactivity (VerifyNow system)
Study: 21481243
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP) 234 mg
Study: 21481243
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP) 156 mg
Study: 21481243
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP) 39 mg
Study: 21482186
Drug: R-miniCHOP (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-miniCHOP (375 mg/m² rituximab, 400 mg/m² cyclophosphamide, 25 mg/m² doxorubicin, 1 mg vincristine, 40 mg/m² prednisone)
Study: 21482862
Drug: Gabapentin plus
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin plus valacyclovir hydrochloride (1000 mg of valacyclovir 3 times a day for 7 days plus gabapentin starting at 300 mg/d, titrated up to 3600 mg/d).
Study: 21487108
Drug: High-dose zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose zidovudine (600 mg orally every 6 hours) and valganciclovir (900 mg orally every 12 hours)
Study: 21487288
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m² on days 1 and 8) and Cisplatin (75 mg/m² on day 1 of each cycle) for three 21-day cycles
Study: 21488082
Drug: HCV treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV treatment eligibility for Black patients
Study: 21488082
Drug: Reasons for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reasons for treatment ineligibility
Study: 21488082
Drug: Treatment completion
Normalized name: piperonyl butoxide
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment completion evaluations
Study: 21489874
Drug: Sentinel-node biopsy
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sentinel-node biopsy with cervical dual injection (technetium and patent blue)
Study: 21492424
Drug: N-terminal pro-brain
Normalized name: Mane 'N Tail Pro-Tect
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-terminal pro-brain natriuretic peptide (NT-proBNP) with cutoff point 1,000 pg/mL
Study: 21492424
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ultrasound comet-tail sign and NT-proBNP
Study: 21494336
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) at doses of 10, 15, 20, and 30 mg worn for 9 hours per day for 7 weeks
Study: 21494336
Drug: Patch testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch testing for DRS scores ≥ 6 or persistent DRS scores ≥ 4
Study: 21494838
Drug: AZD4877 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4877 at 16 mg/day (maximum tolerated dose)
Study: 21494838
Drug: AZD4877 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4877 at 4 mg/day
Study: 21497773
Drug: Carboplatin-based induction
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin-based induction chemotherapy
Study: 21498606
Drug: Humanized anti-CD11a
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Humanized anti-CD11a antibody treatment (weekly subcutaneous for 16 weeks)
Study: 21502084
Drug: Maraviroc 300
Normalized name: maraviroc 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maraviroc 300 mg twice daily for 8 days
Study: 21502553
Drug: Belinostat administered
Normalized name: Belinostat
DrugBank: Belinostat (DB05015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Belinostat administered intravenously at 1 g/m(2) on days 1 to 5 of a 21-day cycle until disease progression or development of intolerance.
Study: 21502953
Drug: GSK1521498 (0.4-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1521498 (0.4-100 mg)
Study: 21502953
Drug: NTX (2-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTX (2-50 mg)
Study: 21503856
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg pegnivacogin
Study: 29096668
Drug: Lenalidomide monotherapy
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide monotherapy
Study: 21504563
Drug: Masitinib (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Masitinib (3 or 6 mg/kg/day)
Study: 21508089
Drug: Maltodextrins and
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrins and leucine (0.035 g . kg(-1) . h(-1))
Study: 21508089
Drug: Maltodextrins (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrins (0.25 g . kg(-1) . h(-1))
Study: 21513761
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine (LAIV), single intranasal dose.
Study: 21516509
Drug: PD-0325901 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-0325901 at 20 mg BID for 21 days followed by 7 days off (initial dose)
Study: 21516509
Drug: PD-0325901 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-0325901 at 15 mg BID (changed dose)
Study: 21516509
Drug: PD-0325901 (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-0325901 (overall treatment)
Study: 21518322
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell therapy (30 mL of bone marrow cultured for MSC growth, injected into one knee)
Study: 21518864
Drug: Antiinflammatory agents
Normalized name: ANTIINFLAMMATORY AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiinflammatory agents
Study: 21524193
Drug: Higher serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher serum insulin secretion relative to serum glucose after a glucose challenge
Study: 21524193
Drug: Model OL
Normalized name: limonen-10-ol, (+)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model OL = 232 - 34.9(ln[ratio insulin/glucose]) - 1.4(adiponectin)
Study: 21524299
Drug: Endothelial dysfunction
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelial dysfunction markers and other clinical parameters (lipids, creatinine, microalbuminuria, blood glucose, HbA1c, blood insulin, high sensitivity C-reactive protein)
Study: 21524303
Drug: Web-based learning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based learning kit plus monthly phone calls
Study: 21524303
Drug: Web-based learning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based learning kit plus all three methods (monthly phone calls, coaching, face-to-face meetings)
Study: 21524303
Drug: Monthly phone
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly phone calls (lowest cost intervention)
Study: 21525850
Drug: 1.5% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% glucose and 0.25% L-carnitine
Study: 21525850
Drug: 2.5% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% glucose solutions
Study: 21525850
Drug: L-carnitine added
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine added to endothelial cells in culture
Study: 21525850
Drug: L-carnitine in
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine in peritoneal dialysis solution
Study: 21529978
Drug: Glitazone treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glitazone treatment
Study: 21530362
Drug: nelfilcon A
Approvals — FDA: no, EMA: no, PMDA: no
Description: nelfilcon A with enhanced lubricating agents (ELDD)
Study: 21530362
Drug: daily disposable
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily disposable contact lenses (DD)
Study: 21531821
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg/d (4 weeks on/2 weeks off)
Study: 21533229
Drug: MRKAd5 HIV-1
Normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRKAd5 HIV-1 gag vaccine
Study: 21538322
Drug: Givinostat (ITF2357)
Normalized name: givinostat
DrugBank: Givinostat (DB12645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Givinostat (ITF2357) administered orally at a dosage of 1.5 mg/kg/day for up to 12 weeks
Study: 21540203
Drug: Non-adjuvanted influenza
Normalized name: Influenza, adjuvanted, quadrivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted influenza A/California/7/2009(H1N1) virus-like strain flu vaccine
Study: 21540460
Drug: Prophylactic infusion
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic infusion of in vitro-generated donor T cells reactive against CML-associated antigens
Study: 21548959
Drug: LA-Cr formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-Cr formula (l-arabinose and chromium) after a 70-gram sucrose challenge
Study: 21549867
Drug: Abdominal subcutaneous
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal subcutaneous adipose tissue (SAT)
Study: 21550951
Drug: Sitagliptin, 100
Normalized name: Metformin HCl-Sitagliptin, 1000 mg-50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin, 100 mg daily
Study: 21550951
Drug: Thiazolidinediones (rosiglitazone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiazolidinediones (rosiglitazone, 8 mg daily or pioglitazone, 45 mg daily)
Study: 21551228
Drug: Lenalidomide 50
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 50 mg daily for 28 days as induction therapy and 10 mg daily for 21 days of a 28-day cycle as maintenance until disease progression or unacceptable toxicity.
Study: 21551511
Drug: TNFα inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFα inhibitor therapy
Study: 21553933
Drug: IgPro20 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgPro20 (subcutaneous administration, 20% solution, initial doses equivalent to 130% of previous IgPro10 doses, adjusted for AUC)
Study: 21553933
Drug: IgPro10 (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgPro10 (intravenous administration, 10% solution)
Study: 21554915
Drug: A/turkey/Turkey/1/2005 (H5N1)
Normalized name: influenza A virus A/turkey/Turkey/1/2005 (H5N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/turkey/Turkey/1/2005 (H5N1) vaccine (3.75 μg HA) with AS03(A)
Study: 21554915
Drug: A/turkey/Turkey/1/2005 (H5N1)
Normalized name: influenza A virus A/turkey/Turkey/1/2005 (H5N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: A/turkey/Turkey/1/2005 (H5N1) vaccine (3.75 μg HA) without AS03(A)
Study: 21554915
Drug: Booster vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster vaccines (adjuvanted or unadjuvanted)
Study: 21555610
Drug: Intravitreal ranibizumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab, injected monthly for 6 months
Study: 21555712
Drug: N(G)-monomethyl-l-arginine (L-NMMA)
Normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-monomethyl-l-arginine (L-NMMA)
Study: 21555744
Drug: N9-GP (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: N9-GP (single IV dose at 25, 50, or 100 U/kg)
Study: 21555744
Drug: Previous FIX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous FIX product (single IV dose at the same dose level)
Study: 21556142
Drug: Control Rabies
Normalized name: rabies virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Rabies vaccine using the 0,1,2-month schedule
Study: 21556950
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin B12 (1500 μg mecobalamin daily for 3 months)
Study: 21556950
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin B12 (1000 μg cyanocobalamin weekly for 5 weeks, then monthly for a total of 3 months)
Study: 21557878
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous ketamine (0.2 mg/kg)
Study: 21558357
Drug: β blockers
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: β blockers with inhaled corticosteroid, long acting β agonist, and long acting antimuscarinic
Study: 21558357
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (inhaled therapy with short acting β agonists or short acting antimuscarinics)
Study: 21558401
Drug: anti-CTLA4 antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-CTLA4 antibody tremelimumab
Study: 21558987
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m² IV) and Cyclophosphamide (600 mg/m² IV) followed by Paclitaxel (175 mg/m² IV or 80 mg/m² IV) combined with Sorafenib (400 mg oral twice a week) for 12 months or less
Study: 21562045
Drug: 1.6 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg/m² once weekly (days 1, 8, 15, and 22; 35-day cycles)
Study: 21562045
Drug: 1.3 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 mg/m² twice weekly (days 1, 4, 8, and 11; 21-day cycles)
Study: 21562045
Drug: 1.3 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3 mg/m² twice weekly
Study: 21562045
Drug: 1.6 mg/m²
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg/m² once weekly
Study: 21565903
Drug: Preemptive antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive antifungal therapy
Study: 21566092
Drug: alemtuzumab at
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: alemtuzumab at 30 mg IV 3 times weekly for up to 12 weeks after test dosing
Study: 21566413
Drug: Valrubicin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valrubicin (800 mg, 6 weekly intravesical treatments)
Study: 21569187
Drug: Atazanavir/RTV 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/RTV 300/100 mg
Study: 21569187
Drug: Atazanavir/RTV 400/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/RTV 400/100 mg
Study: 21569313
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg daily for 8 weeks
Study: 21569559
Drug: 12.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg/day prednisone
Study: 21570199
Drug: Chemoradiotherapy (gemcitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (gemcitabine, bevacizumab, and radiation therapy)
Study: 21570386
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (4000-40,000 IU/d) with calcium (1200 mg/d)
Study: 21575194
Drug: Trazodone (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (50-300 mg/day) for 12 weeks
Study: 21575194
Drug: Trazodone (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (50-300 mg/day) + Pregabalin (75-450 mg/day) for an additional 12 weeks
Study: 21576653
Drug: CRT-D (Cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT-D (Cardiac Resynchronization Therapy Defibrillator)
Study: 21586342
Drug: perindopril (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: perindopril (8 mg) plus amlodipine (10mg)
Study: 21586916
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) treatment for 12 weeks
Study: 21590520
Drug: Dronabinol (2.5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (2.5-15 mg/day)
Study: 21592098
Drug: SumaRT/Nap (sumatriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: SumaRT/Nap (sumatriptan 85 mg and naproxen 500 mg)
Study: 21592098
Drug: Usual migraine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual migraine medication
Study: 21595953
Drug: Super-selective arterial
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super-selective arterial infusion of gemcitabine over 24 hours via subcutaneous indwelling port.
Study: 21595953
Drug: Super-selective arterial
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Super-selective arterial infusion of gemcitabine.
Study: 21596084
Drug: VAX125 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAX125 vaccine at a dose of 5 μg
Study: 21596084
Drug: VAX125 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAX125 vaccine at a dose of 8 μg
Study: 21596084
Drug: Combined 5
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 5 and 8 μg groups
Study: 21596852
Drug: RVDD (lenalidomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVDD (lenalidomide 25 mg, bortezomib 1.3 mg/m(2), pegylated liposomal doxorubicin 30 mg/m(2), dexamethasone 20/10 mg)
Study: 21604935
Drug: Active annual
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active annual screening program of PSA screening for six rounds, four of which had accompanying digital rectal examination (DRE)
Study: 21606412
Drug: Cabozantinib (XL184)
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib (XL184) 175 mg daily
Study: 21607190
Drug: Adapalene 0.1%/Benzoyl
Normalized name: ADAPALENE 0.1%/BENZOYL PEROXIDE 2.5% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel
Study: 21607774
Drug: High-dose rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rate balloon brachytherapy (HDRBB) delivering 34 Gy in 10 fractions
Study: 21609134
Drug: rAAV1-CB-hAAT administered
Normalized name: BroveX CB
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV1-CB-hAAT administered by intramuscular injection at doses of 6.0×10(11), 1.9×10(12), and 6.0×10(12) vector genomes/kg (n=3 subjects/dose)
Study: 21612836
Drug: NGX-4010, capsaicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGX-4010, capsaicin 8% patch
Study: 21613261
Drug: Decitabine delivered
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine delivered at 20 mg/m² by 1-hour infusion (Arm A) for 3, 5, or 7 days before standard induction chemotherapy.
Study: 21613261
Drug: Decitabine delivered
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine delivered at 20 mg/m² by continuous infusion (Arm B) for 3, 5, or 7 days before standard induction chemotherapy.
Study: 21613261
Drug: Standard induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard induction chemotherapy with infusional cytarabine (100 mg/m² for 7 days) and daunorubicin (60 mg/m² × 3 doses).
Study: 21619670
Drug: Fara'd dates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fara'd dates (50 g equivalent of available carbohydrates)
Study: 21619670
Drug: Lulu dates
Normalized name: Date
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lulu dates (50 g equivalent of available carbohydrates)
Study: 21619670
Drug: Bo ma'an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bo ma'an dates (50 g equivalent of available carbohydrates)
Study: 21619670
Drug: Dabbas dates
Normalized name: Date
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabbas dates (50 g equivalent of available carbohydrates)
Study: 21619670
Drug: Khalas dates
Normalized name: Date
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Khalas dates (50 g equivalent of available carbohydrates)
Study: 21619670
Drug: Fara'd dates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fara'd dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Study: 21619670
Drug: Lulu dates
Normalized name: Date
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lulu dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Study: 21619670
Drug: Bo ma'an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bo ma'an dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Study: 21619670
Drug: Dabbas dates
Normalized name: Date
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabbas dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Study: 21619670
Drug: Khalas dates
Normalized name: Date
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Khalas dates for type 2 diabetes (50 g equivalent of available carbohydrates)
Study: 21619692
Drug: Brazil nuts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nuts (BNG), n = 8, 15-25 g/day (equivalent to 3 to 5 units/day)
Study: 21619692
Drug: Placebo (PG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PG, lactose), n = 9, one capsule/day